{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T07:47:43Z","timestamp":1793346463769,"version":"4.5.0"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:00:00Z","timestamp":1761868800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Heart Journal"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.ahj.2025.107295","type":"journal-article","created":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T00:11:07Z","timestamp":1762215067000},"page":"107295","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Evolocumab before percutaneous coronary intervention for acute myocardial infarction: Design of the AMUNDSEN trial"],"prefix":"10.1016","volume":"292","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0824-6809","authenticated-orcid":false,"given":"Gilles","family":"Montalescot","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonardo","family":"Bolognese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stanislaw","family":"Bartus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angel","family":"Cequier-Fillat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Holger","family":"Thiele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Mach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Wouter","family":"Jukema","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emile","family":"Ferrari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00e9raud","family":"Souteyrand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Bouleti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gr\u00e9goire","family":"Range","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Chioccioli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9a","family":"Picchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laure","family":"Batias-Moreau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Esposito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nassim","family":"Braik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nassim","family":"Redjimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Duband","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Guedeney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Zeitouni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karine","family":"Brochard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanne","family":"Silvain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Vicaut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ahj.2025.107295_bib0001","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"41","author":"Mach","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ahj.2025.107295_bib0002","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1016\/j.jcmg.2022.03.002","article-title":"Effect of evolocumab on changes in coronary plaque phenotype and burden in statin-treated patients following myocardial infarction","volume":"15","author":"Nicholls","year":"2022","journal-title":"J Am Coll Cardiol Img"},{"key":"10.1016\/j.ahj.2025.107295_bib0003","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1001\/jama.2022.5218","article-title":"Effect of alirocumab added to high-intensity statin on coronary atherosclerosis in patients with acute myocardial infarction","volume":"327","author":"R\u00e4ber","year":"2022","journal-title":"JAMA"},{"key":"10.1016\/j.ahj.2025.107295_bib0004","doi-asserted-by":"crossref","first-page":"2452","DOI":"10.1016\/j.jacc.2019.08.010","article-title":"Evolocumab for early reduction of LDL cholesterol levels in patients with acute coronary syndromes (EVOPACS)","volume":"74","author":"Koskinas","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2025.107295_bib0005","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1097\/FJC.0000000000000706","article-title":"Alirocumab in acute myocardial infarction: results from the VA Commonwealth University Alirocumab Response Trial (VCU-AlirocRT)","volume":"74","author":"Trankle","year":"2019","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.ahj.2025.107295_bib0006","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1161\/CIRCULATIONAHA.120.046320","article-title":"Effect of evolocumab on atherogenic lipoproteins during the peri- and early postinfarction period","volume":"142","author":"Leucker","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2025.107295_bib0007","doi-asserted-by":"crossref","first-page":"2571","DOI":"10.1016\/j.jcmg.2019.06.022","article-title":"PCSK9 antibody alirocumab attenuates arterial wall inflammation without changes in circulating inflammatory markers","volume":"12","author":"Hoogeveen","year":"2019","journal-title":"J Am Coll Cardiol Img"},{"key":"10.1016\/j.ahj.2025.107295_bib0008","doi-asserted-by":"crossref","first-page":"5040","DOI":"10.3390\/jcm13175040","article-title":"Proprotein convertase subtilisin\/kexin type 9 inhibitors in patients following acute coronary syndromes: from lipid lowering and plaque stabilization to improved outcomes","volume":"13","author":"Dimitriadis","year":"2024","journal-title":"J Clin Med"},{"key":"10.1016\/j.ahj.2025.107295_bib0009","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.101933","article-title":"Lim SW for the RACING investigators. Efficacy and safety of moderate-intensity statin with ezetimibe combination therapy in patients after percutaneous coronary intervention: a post-hoc analysis of the RACING trial","volume":"58","author":"Park","year":"2023","journal-title":"eClinicalMedicine"},{"key":"10.1016\/j.ahj.2025.107295_bib0010","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1016\/j.jacc.2025.02.007","article-title":"Early ezetimibe initiation after myocardial infarction protects against later cardiovascular outcomes in the SWEDEHEART registry","volume":"85","author":"Leosdottir","year":"2025","journal-title":"JACC"},{"issue":"5","key":"10.1016\/j.ahj.2025.107295_bib0011","doi-asserted-by":"crossref","first-page":"190","DOI":"10.31083\/j.rcm2505190","article-title":"Review of Evolocumab for the reduction of LDL cholesterol and secondary prevention of atherosclerotic cardiovascular disease","volume":"25","author":"Leiter","year":"2024","journal-title":"Rev Cardiovasc Med"},{"key":"10.1016\/j.ahj.2025.107295_bib0012","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2025.107295_bib0013","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1093\/eurheartj\/ehu505","article-title":"Cardiovascular risk in post-myocardial infarction patients: nationwide real world data demonstrate the importance of a long-term perspective","volume":"36","author":"Jernberg","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ahj.2025.107295_bib0014","doi-asserted-by":"crossref","first-page":"383","DOI":"10.2147\/VHRM.S162004","volume":"14","author":"Degli Esposti","year":"2018","journal-title":"Vasc Health Risk Manag"},{"key":"10.1016\/j.ahj.2025.107295_bib0015","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1016\/S0140-6736(23)00351-3","article-title":"Immediate vs staged complete revascularisation in patients presenting with acute coronary syndrome and multivessel coronary disease (BIOVASC): a prospective, open-label, non-inferiority, randomised trial","volume":"401","author":"Diletti","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.ahj.2025.107295_bib0016","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/j.jacc.2019.12.026","article-title":"Readmission and mortality after hospitalization for myocardial infarction and heart failure","volume":"75","author":"Ko","year":"2020","journal-title":"JACC"},{"key":"10.1016\/j.ahj.2025.107295_bib0017","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1161\/CIRCULATIONAHA.116.024993","article-title":"Sex differences in 1-year all-cause rehospitalization in patients after acute myocardial infarction: a prospective observational study","volume":"135","author":"Dreyer","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2025.107295_bib0018","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1186\/s12872-024-04057-w","article-title":"Early administration of proprotein convertase subtilisin\/kexin type 9 (PCSK9) inhibitors in patients with acute coronary syndrome: a systematic review and meta-analysis","volume":"24","author":"Hosseini","year":"2024","journal-title":"BMC Cardiovasc Disord"},{"key":"10.1016\/j.ahj.2025.107295_bib0019","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1161\/CIRCULATIONAHA.110.002451","article-title":"Clinical benefit of statin pretreatment in patients undergoing percutaneous coronary intervention: a collaborative patient-level meta-analysis of 13 randomized studies","volume":"123","author":"Patti","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2025.107295_bib0020","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1016\/j.amjcard.2014.02.034","article-title":"Meta-analysis of time-related benefits of statin therapy in patients with acute coronary syndrome undergoing percutaneous coronary intervention","volume":"113","author":"Navarese","year":"2014","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ahj.2025.107295_bib0021","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1001\/jamacardio.2018.3408","article-title":"Timing of loading dose of atorvastatin in patients undergoing percutaneous coronary intervention for acute coronary syndromes: insights from the SECURE-PCI randomized clinical trial","volume":"3","author":"Lopes","year":"2018","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.ahj.2025.107295_bib0022","first-page":"1383","article-title":"Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)","volume":"344","year":"1994","journal-title":"Lancet"},{"key":"10.1016\/j.ahj.2025.107295_bib0023","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1001\/jama.285.13.1711","article-title":"Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial","volume":"285","author":"Schwartz","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.ahj.2025.107295_bib0024","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1056\/NEJMoa040583","article-title":"Intensive vs moderate lipid lowering with statins after acute coronary syndromes","volume":"350","author":"Cannon","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2025.107295_bib0025","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","article-title":"Alirocumab and cardiovascular outcomes after acute coronary syndrome","volume":"379","author":"Schwartz","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2025.107295_bib0026","doi-asserted-by":"crossref","first-page":"433","DOI":"10.2217\/fca-2018-0067","article-title":"Inclisiran for the treatment of cardiovascular disease: the ORION clinical development program","volume":"6","author":"Stoekenbroek","year":"2018","journal-title":"Future Cardiol"},{"issue":"14","key":"10.1016\/j.ahj.2025.107295_bib0027","first-page":"1333","article-title":"Long-term evolocumab in patients with multivessel coronary disease after myocardial infarction","volume":"83","author":"O\u2019Donoghue","year":"2024","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"10.1016\/j.ahj.2025.107295_bib0028","first-page":"512","article-title":"Reduction in total cardiovascular events with evolocumab therapy: the FOURIER-OLE trial","volume":"85","author":"Murphy","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2025.107295_bib0029","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1016\/j.jacc.2023.08.019","article-title":"Concomitant coronary atheroma regression and stabilization in response to lipid-lowering therapy","volume":"82","author":"Biccir\u00e8","year":"2023","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"10.1016\/j.ahj.2025.107295_bib0030","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.jacc.2020.11.011","article-title":"Effect of Evolocumab on complex coronary disease requiring revascularization","volume":"77","author":"Oyama","year":"2021","journal-title":"J Am Coll Cardiol"}],"container-title":["American Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870325003576?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870325003576?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T08:20:14Z","timestamp":1780906814000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002870325003576"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":30,"alternative-id":["S0002870325003576"],"URL":"https:\/\/doi.org\/10.1016\/j.ahj.2025.107295","relation":{},"ISSN":["0002-8703"],"issn-type":[{"value":"0002-8703","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evolocumab before percutaneous coronary intervention for acute myocardial infarction: Design of the AMUNDSEN trial","name":"articletitle","label":"Article Title"},{"value":"American Heart Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ahj.2025.107295","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"107295"}}